MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
By Michael Weller, R. Stupp, Guido Reifenberger, A. Brandes, M. Bent, Wolfgang Wick, M. Hegi. Nature Reviews Neurology, 2010
766 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/466d3f0d76e90af167572e4dd501f0cc54ca7c9f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- C. Lord
- T. Kelly
- Michael Weller
- Manel Esteller
- Guido Reifenberger
- Manuel Rodríguez‐Paredes
- Alan Ashworth
- Peter A. Jones
In Molecular Biology
- Peter A. Jones
- Manel Esteller
- C. Lord
- T. Kelly
- M. Kulis
- Alan Ashworth
- Daniel D. De Carvalho
- Manuel Rodríguez‐Paredes
Citations in the corpus
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “For a detailed discussion, the reader is referred to recent extensive reviews [18].”
- Cancer epigenetics reaches mainstream oncology (2011, background): “Many studies have now confirmed these findings about temozolomide-based glioblastoma treatment in many different geographical area”
- DNA methylation and cancer. (2010, background): “This is the case forMGMT (O-6-methylguanineDNMT), which in normal tissues averts the negative effect of DNA alkylation and was shown to be silenced in many types of carcinomas (Esteller et al., 1999; Weller et al., 2010).”
- Epigenetic Modifications as Therapeutic Targets (2010, background): “Expression of the DNA repair gene O(6)-methylguanine-DNA methyltransferase ( MGMT ) antagonizes chemotherapy and radiation treatmen”
- The DNA damage response and cancer therapy (2012, methodology): “MGMT methylation has also been implicated in the response of tumours (such as gliomas) to temozolomide, and is now being used as a biomarker to direct the use of therap”
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas (2010, background): “MGMT promoter methylation status has been demonstrated as a powerful prognostic and predictive marker for patients with glioblastomas [8, 24].”